C-CGEYMetroBiotech
NAD+ precursors, NAD+ biology, healthspan
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CGEY
C-CGEYC-CGEYNAD+ precursors, NAD+ biology, healthspan
0-100 chain-logic scale · 15 dimensions · scored on public evidence
No company beliefs, mission, or theory statements are visible in the provided 2013-06-13 Wayback snapshot text; the visible content consists only of Wayback Machine capture metadata, so no substantive company position can be extracted from this snapshot alone.
SourceMetroBiotech presented the view that age-related decline in NAD+ is an important driver of loss of health and metabolism, and that developing proprietary NAD+ precursors or enhancers could restore this biology and help treat diseases of aging while extending healthy lifespan.
SourceMetroBiotech’s stated position was that NAD+ is essential for normal cellular function, that NAD+ levels decline with age, and that restoring or increasing NAD+ could preserve health and normal metabolism with broad pharmaceutical potential. The company framed reduced NAD+ as linked to aging and to disease processes such as mitochondrial dysfunction and inflammation, implying that NAD+-boosting therapeutics could target the root biology of age-related decline rather than isolated symptoms.
SourceMetro International Biotech stated that NAD+ is essential to the function of all living cells, that NAD+ levels decline with age, and that raising or maintaining NAD+ has broad therapeutic potential to preserve health and normal metabolism. The company presented this as the basis for developing NAD+-based pharmaceuticals, especially for rare mitochondrial diseases, with the view that higher NAD+ can support mitochondrial biogenesis and other natural pathways tied to mitochondrial health and age-related functional decline.
SourceMetroBiotech states that NAD+ is critically important to the function of all living cells, that NAD+ levels decline with age, and that increasing NAD+ through first-in-class small-molecule enhancers has broad therapeutic potential to preserve health and normal metabolism while treating disease.
SourceMetro International Biotech states that NAD+ is critically important to the function of all living cells, that NAD+ levels decline with human age, and that increasing NAD+ has broad therapeutic potential to preserve health and normal metabolism. The company presents its drug platform as creating first-in-class small-molecule NAD+ enhancers that leverage the NAD+ cycle to treat rare diseases and improve human health against adverse conditions of aging, with an initial focus on rare mitochondrial diseases.
SourceNo company beliefs, mission, or theory statements are visible in the provided 2010-05-08 Wayback snapshot text; the visible content consists only of Internet Archive/Wayback metadata rather than MetroBiotech page content.
SourceThis Wayback snapshot does not display any company beliefs, mission, or longevity theory content. The visible page is an Internet Archive error page stating that the MetroBiotech page could not be displayed, so no substantive company stance can be extracted from this capture itself.
SourceNo company beliefs, mission, or theory statements are visible in this snapshot; the archived page displays an error message instead of company content.
Source